Barry Melancon, Former CEO of AICPA, Joins Caseware as Chair of Global Advisory Board 8-04-2025, 19:50

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Banle Energy Launches Its First Biofuel Bunkering Operation in Hong Kong 14-07-2023, 19:46